4.4 Article

Timing of uveitis onset in oligoarticular juvenile idiopathic arthritis (JIA) is the main predictor of severe course uveitis

Journal

ACTA OPHTHALMOLOGICA
Volume 90, Issue 1, Pages 91-95

Publisher

WILEY-BLACKWELL
DOI: 10.1111/j.1755-3768.2009.01815.x

Keywords

juvenile idiopathic arthritis; outcomes; risk factors; uveitis; vision

Categories

Funding

  1. 'Il Volo' Association for Rheumatic Diseases in Children

Ask authors/readers for more resources

Purpose: Aim of the present study was to validate a statistical model to predict a severe course of anterior uveitis (AU) in patients with juvenile idiopathic arthritis (JIA). Methods: Consecutive patients with newly diagnosed uveitis have been followed for at least 1 year with a standardized protocol. For each patient, demographic, clinical and laboratory characteristics, including time interval between arthritis and uveitis onset, alpha(2)-globulins level at arthritis onset, number of uveitis relapses/year, ocular complications and therapy and visual acuity, have reported. The validation procedure included the assessment of sensitivity, specificity and efficiency of previously published statistical model (Zulian et al. J Rheumatol 2002; 29: 2446-2453) in a new inception cohort of patients during a short length follow-up. Results: Sixty patients with JIA, followed at 14 paediatric rheumatology-ophthalmology centres in Italy, entered the study. The mean age at arthritis onset was 4.4 years (range 1.2-15.8 years), and the mean interval time between arthritis and uveitis onset was 1.8 years (range: 0.0-14.2 years). After the first AU, patients, followed for a mean of 3.2 years, had a mean of 2.9 uveitis relapses. Twenty-two patients (36.7%) presented at least one complication. Using a probability cut-off value = 0.7, the statistical model revealed 80% sensitivity, 58% specificity and 65% efficiency. Conclusion: The time interval between arthritis and uveitis onset resulted as the main predictor of severe course uveitis in JIA. The statistical model was able to predict the development of a severe course in 8 of 10 patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Rheumatology

Methotrexate in Linear Scleroderma: Long-Term Efficacy in Fifty Children From a Single Pediatric Rheumatology Center

Gloria Fadanelli, Anna Agazzi, Fabio Vittadello, Alessandra Meneghel, Francesco Zulian, Giorgia Martini

Summary: Most children with linear scleroderma respond well to methotrexate treatment, achieving complete and long-lasting remission. The overall aesthetic and functional sequelae are moderate, likely due to early establishment of tissue damage and stabilization of the damage through treatment. Early diagnosis, methotrexate treatment, and long-term monitoring are crucial for improving outcomes and promptly identifying flares.

ARTHRITIS CARE & RESEARCH (2021)

Article Rheumatology

Early detection of ventricular dysfunction in juvenile systemic sclerosis by speckle tracking echocardiography

Giovanni Civieri, Biagio Castaldi, Giorgia Martini, Alessandra Meneghel, Ornella Milanesi, Francesco Zulian

Summary: Speckle tracking echocardiography (STE) is more sensitive in identifying cardiac involvement in juvenile systemic sclerosis (JSSc) patients and can detect dysfunction earlier than traditional techniques. Over time, there was a gradual worsening of left ventricular global longitudinal strain (LV-GLS) which preceded the decrease in ejection fraction (EF).

RHEUMATOLOGY (2021)

Article Rheumatology

Mycophenolate mofetil for methotrexate-resistant juvenile localized scleroderma

Giorgia Martini, Laura Saggioro, Roberta Culpo, Fabio Vittadello, Alessandra Meneghel, Francesco Zulian

Summary: This study investigated the safety and efficacy of MMF in patients with severe or MTX-refractory juvenile localized scleroderma. After a mean follow-up of 9.4 years, both MMF and MTX were effective in controlling disease activity. While there was no significant difference in relapse-free survival between the two groups, MMF may induce more persistent remission.

RHEUMATOLOGY (2021)

Article Rheumatology

Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis

Nicolino Ruperto, Hermine Brunner, Nikolay Tzaribachev, Gabriel Vega-Cornejo, Ingrid Louw, Rolando Cimaz, Jason Dare, Graciela Espada, Enrique Faugier, Manuel Ferrandiz, Valeria Gerloni, Pierre Quartier, Clovis Artur Silva, Linda Wagner-Weiner, Yash Gandhi, Julie Passarell, Marleen Nys, Robert Wong, Alberto Martini, Daniel J. Lovell

Summary: In patients aged 2-17 years with pJIA, no evidence of association between higher levels of exposure to IV ABA or SC ABA and incidence of infection was observed.

JOURNAL OF RHEUMATOLOGY (2021)

Article Pediatrics

Case Report: Life-Threatening Macrophage Activation Syndrome With Fulminant Myocarditis Successfully Rescued by High Dose Intravenous Anakinra

Alessandra Meneghel, Giorgia Martini, Angela Amigoni, Andrea Pettenazzo, Massimo Padalino, Francesco Zulian

Summary: This case report highlights the importance of early aggressive treatment in refractory life-threatening sJIA-related MAS and provides evidence on the safety and efficacy of high dose intravenous Anakinra in acute myocarditis requiring VA-ECMO support.

FRONTIERS IN PEDIATRICS (2021)

Editorial Material Rheumatology

Ballet foot in a boy

Teresa Giani, Maurizio Gattinara, Rolando Cimaz

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2021)

Letter Dermatology

Terry's nails sign in a girl with autoimmune hypothyroidism and familial hyper-CK-emia

Enrico Valerio, Ramon Grimalt, Francesco Zulian, Vera Perri, Mario Cutrone

INTERNATIONAL JOURNAL OF DERMATOLOGY (2022)

Article Ophthalmology

Methotrexate Monotherapy in Juvenile Idiopathic Arthritis Associated Uveitis: Myth or Reality?

Francesca Tirelli, Maria Elisabetta Zannin, Fabio Vittadello, Jacopo Agnolucci, Monica Mazzarolo, Francesco Zulian

Summary: The study evaluated the long-term efficacy of MTX monotherapy in patients with JIA-U and found that although effective in the early stages, MTX showed poor disease control in the long term, with many patients eventually needing biologic agents for treatment.

OCULAR IMMUNOLOGY AND INFLAMMATION (2022)

Article Rheumatology

Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort

Arianna De Matteis, Claudia Bracaglia, Denise Pires Marafon, Anna Lucia Piscitelli, Maria Alessio, Roberta Naddei, Francesca Orlando, Giovanni Filocamo, Francesca Minoia, Angelo Ravelli, Jessica Tibaldi, Rolando Cimaz, Achille Marino, Gabriele Simonini, Maria Vincenza Mastrolia, Francesco La Torre, Ilaria Tricarico, Francesco Licciardi, Davide Montin, Maria Cristina Maggio, Clotilde Alizzi, Giorgia Martini, Adele Civino, Romina Gallizzi, Alma Nunzia Olivieri, Francesca Ardenti Morini, Giovanni Conti, Fabrizio De Benedetti, Manuela Pardeo

Summary: This study used real-world data to evaluate the effectiveness and safety of canakinumab in Italian patients with sJIA. The results showed that canakinumab was effective in treating sJIA and had no serious adverse events. The history of MAS and higher number of active joints were associated with poorer treatment outcomes.

RHEUMATOLOGY (2022)

Article Rheumatology

Systemic sclerosis sine scleroderma in children

Francesco Zulian, Gloria Lanzoni, Biagio Castaldi, Alessandra Meneghel, Francesca Tirelli, Elisabetta Zanatta, Giorgia Martini

Summary: This study reports the first case series of patients with ssJSSc, a rare condition in childhood characterized by no skin involvement. Compared to classic JSSc, ssJSSc showed a longer diagnostic delay, higher frequency of cardiac involvement, and worse outcomes.

RHEUMATOLOGY (2022)

Review Pediatrics

Drug Treatment of Low Bone Mass and Other Bone Conditions in Pediatric Patients

Stefania Costi, Teresa Giani, Francesco Orsini, Rolando Cimaz

Summary: Osteoporosis can affect young individuals, although it is rare. Bone mass increases during childhood and peaks between the second and third decades, then gradually declines. Various factors, such as genetic disorders, chronic illnesses, and certain medications, can impact bone health. Diagnosis in young patients is based on the criteria defined by the International Society for Clinical Densitometry (ISCD) in 2013. Identification and monitoring of high-risk factors are important. Simple interventions, such as addressing underlying causes, minimizing negative effects of medications on bone, or increasing calcium and vitamin D intake, can protect bone mass. Pharmacological treatment may be necessary in selected cases. Bisphosphonates are the main therapeutic agent for children with significant skeletal fragility and can also be used for other bone conditions. Denosumab, an anti-RANKL antibody, could be an alternative treatment option. Long-term effects and safety of denosumab in children are currently being evaluated in clinical trials.

PEDIATRIC DRUGS (2022)

Review Acoustics

Ultrasound versus physical examination in predicting disease flare in children with juvenile idiopathic arthritis: a systematic literature review and qualitative synthesis

Orazio De Lucia, Teresa Giani, Roberto Caporali, Rolando Cimaz

Summary: This systematic review analyzed the predictive value of ultrasound (US) in assessing subclinical synovitis in juvenile idiopathic arthritis (JIA). The study found that US may have the potential to predict flare in JIA, but more research is needed to draw definitive conclusions.

MEDICAL ULTRASONOGRAPHY (2022)

Article Rheumatology

Canakinumab treatment in a young girl with refractory chronic recurrent multifocal osteomyelitis associated with pyoderma gangrenosum

Sabrina Acierno, Francesca Angrisani, Achille Marino, Roberto Felice Caporali, Rolando Cimaz, Teresa Giani

Summary: CRMO is a bone inflammatory disorder characterized by osteolytic lesions, with no standardized therapies available. Treatment with an anti-IL-1 beta antibody may show promise in managing the condition.

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2022)

Article Pediatrics

Case report: Exploring under the tip of the iceberg: A case series of self-limiting multisystem inflammatory syndrome in children

Alessandra Meneghel, Giorgia Martini, Marta Balzarin, Nadia Zabadneh, Michele Fastiggi, Francesca Tirelli, Francesco Zulian

Summary: Multisystem inflammatory syndrome in children (MIS-C) is a serious condition caused by SARS-COV-2 infection, characterized by persistent fever, multiorgan dysfunction, and increased inflammation. We report a series of four patients with self-limiting MIS-C, who did not require immunomodulatory treatment. There is limited knowledge about self-limiting MIS-C and no information on medium- and long-term outcomes for this subset of patients has been reported.

FRONTIERS IN PEDIATRICS (2022)

Article Medicine, General & Internal

Proposal of an Algorithm to Early Detect Attenuated Type I Mucopolysaccharidosis (MPS Ia) among Children with Growth Abnormalities

Federico Baronio, Stefano Zucchini, Francesco Zulian, Mariacarolina Salerno, Rossella Parini, Alessandro Cattoni, Federica Deodato, Alberto Gaeta, Carla Bizzarri, Serena Gasperini, Andrea Pession

Summary: Diagnostic delay is common in MPS Ia due to the rarity of the disease and the variability of clinical presentation. A multidisciplinary panel developed an algorithm to improve awareness and reduce diagnostic delay of MPS Ia in pediatric endocrinologists.

MEDICINA-LITHUANIA (2022)

No Data Available